Sanofi (EPA:SAN)
79.00
+1.28 (1.65%)
Feb 19, 2026, 5:36 PM CET
Sanofi Revenue
In the year 2025, Sanofi had annual revenue of 46.72B EUR with 5.49% growth. Sanofi had revenue of 12.21B in the quarter ending December 31, 2025, with 6.87% growth.
Revenue
46.72B
Revenue Growth
+5.49%
P/S Ratio
2.01
Revenue / Employee
624.16K
Employees
82,878
Market Cap
93.85B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 46.72B | 2.43B | 5.49% |
| Dec 31, 2024 | 44.29B | 2.67B | 6.41% |
| Dec 31, 2023 | 41.62B | 1.06B | 2.61% |
| Dec 31, 2022 | 40.56B | 1.39B | 3.54% |
| Dec 31, 2021 | 39.18B | 1.81B | 4.83% |
| Dec 31, 2020 | 37.37B | -262.00M | -0.70% |
| Dec 31, 2019 | 37.63B | 1.95B | 5.48% |
| Dec 31, 2018 | 35.68B | -544.00M | -1.50% |
| Dec 31, 2017 | 36.22B | 1.53B | 4.40% |
| Dec 31, 2016 | 34.70B | -165.00M | -0.47% |
| Dec 31, 2015 | 34.86B | 2.86B | 8.94% |
| Dec 31, 2014 | 32.00B | 708.00M | 2.26% |
| Dec 31, 2013 | 31.29B | -4.67B | -12.98% |
| Dec 31, 2012 | 35.96B | 899.00M | 2.56% |
| Dec 31, 2011 | 35.06B | 1.02B | 3.00% |
| Dec 31, 2010 | 34.04B | 2.80B | 8.98% |
| Dec 31, 2009 | 31.23B | 2.42B | 8.38% |
| Dec 31, 2008 | 28.82B | -390.00M | -1.34% |
| Dec 31, 2007 | 29.21B | -282.00M | -0.96% |
| Dec 31, 2006 | 29.49B | 976.00M | 3.42% |
| Dec 31, 2005 | 28.51B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| EssilorLuxottica Société anonyme | 28.49B |
| Eurofins Scientific SE | 7.30B |
| emeis Société anonyme | 5.77B |
| Clariane SE | 5.31B |
| Ramsay Générale de Santé | 5.24B |
| bioMérieux | 4.12B |
| Ipsen | 3.93B |
| Sartorius Stedim Biotech | 2.97B |
Sanofi News
- 1 day ago - Press release: Filing of the 2025 U.S. Form 20-F and French “Document d'Enregistrement Universel” containing the Annual Financial Report - GlobeNewsWire
- 2 days ago - Sanofi, Teva Report Positive Phase 2b Results For Duvakitug - Nasdaq
- 2 days ago - Sanofi announces leadership evolution in Specialty Care Business Unit - PRNewsWire
- 2 days ago - Teva, Sanofi's Phase 2b Trial Of Duvakitug Shows Durable Efficacy In UC & Crohn's - Nasdaq
- 2 days ago - Teva Pharmaceutical's New Study Shows Lasting Relief For Inflammatory Bowel Disease Patients - Benzinga
- 2 days ago - Teva (TEVA) and Sanofi Report Positive Results for Duvakitug in UC and Crohn's - GuruFocus
- 2 days ago - Teva, Sanofi report durable phase 2b efficacy for duvakitug in ulcerative colitis, Crohn’s disease - Seeking Alpha
- 2 days ago - Press Release: Sanofi and Teva's duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn's disease - GlobeNewsWire